Not available
Quote | vTv Therapeutics Inc. (NASDAQ:VTVT)
Last: | $23.33 |
---|---|
Change Percent: | -4.96% |
Open: | $24.95 |
Close: | $23.33 |
High: | $24.95 |
Low: | $23.33 |
Volume: | 1,322 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | vTv Therapeutics Inc. (NASDAQ:VTVT)
2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING PR Newswire WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developi...
Message Board Posts | vTv Therapeutics Inc. (NASDAQ:VTVT)
Subject | By | Source | When |
---|---|---|---|
2 week long runs in past on news | 81vette | investorshub | 03/06/2023 5:28:28 PM |
Zero borrow and not optionable,low float target $4,insider | 81vette | investorshub | 03/06/2023 3:06:16 PM |
Zero borrow and not optionable,low float target $4,insider | 81vette | investorshub | 03/06/2023 3:06:15 PM |
https://finviz.com/quote.ashx?t=VTVT&ty=c&ta=1&p=d | TheFinalCD | investorshub | 02/27/2023 1:03:17 PM |
whytestocks: $VTVT News Article - vTv Therapeutics Announces Paul Sekhri as new President and Chief | whytestocks | investorshangout | 07/27/2022 12:11:01 PM |
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING PR Newswire WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developi...
HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter e...
2024-04-16 19:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...